Traditional laboratory parameters and IFNγ-related biomarkers in the diagnosis and management of macrophage activation syndrome (MAS)
Authors' conclusion
These findings highlight the potential role of CXCL9 measurement in supporting the diagnosis and guiding the therapeutic management of patients with MAS in clinical practice.
Study context
- Population
- Patients with MAS secondary to Still's disease and patients with active pediatric Still's disease, six Italian centres
- Participants
- 41 vs 24
- Comparison
- MAS secondary to Still's disease vs active pediatric Still's disease
- MASn = 41
- Active SDn = 24reference
- Outcome
- Diagnostic and prognostic significance of traditional laboratory parameters of hyperinflammation and of IFNγ-related biomarkers (IL-18, CXCL9, neopterin) in MAS
Methodological detailsmulticentre
- Multicentre
Performance
As reported in the abstract
Discrimination of MAS from active SD; prognosis of severe MAS · baseline
Prognostic score (baseline CXCL9 + ferritin, platelet count, fibrinogen, LDH) for severe MAS: sensitivity
100 %
Prognostic score for severe MAS: specificity
74 %
Further findings
Risk of failing to achieve MAS remission in ≤2 months, by IFNγ-related biomarker levels at T1 (contingency analysis) · T1 (5-15 days from baseline)
| OR for failing to achieve MAS remission in ≤2 months | |
|---|---|
| CXCL9 >830 pg/ml at T1Significant risk as printed | 9.3 |
| IL-18 >83,000 pg/ml at T1Significant risk as printed | 5.4 |
Original publication
Traditional laboratory parameters and IFNγ-related biomarkers in the diagnosis and management of MAS. Semin Arthritis Rheum. Published 12 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →